



Rômison Rodrigues Mota leaves the position after a request for review delays the norm's vote; the topic will return to the regulatory agenda for 2026-2027
Entity reinforces that personalized preparations are essential when industrialized products do not meet clinical needs
According to Marcelo Polacow Bisson, excluding pharmacies' manipulation leads to lack of assistance; Anvisa's proposed text on the Cannabis regulation is also criticized for bypassing procedural rites
Proposal in the review of RDC 327/2019 to RDC 660/2022 divides opinions and raises doubts about access and judicialization
The submission of scientific evidence is essential to support the regulation of cannabis cultivation in Brazil and complies with STJ's determination
Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence
Rapporteur Rômison Mota advocated for changes impacting imports via RDC 660; new rule prioritizes national products when there is equivalence
Norm that regulates manufacturing, importation, prescription, and inspection may be entirely revoked and replaced by a new regulatory framework; decision will be made at the Collegiate Board meeting.
Publication in the Official Gazette of this Monday (8) details the approval of the 100 mg/ml oral solution
Submission of registrations, videos, and requests for confidentiality ends at 11:59 pm this Friday (5); item revising rules for cannabis products will be defined at the Dicol meeting on December 10
Public call aims to gather scientific evidence to support the regulation of Cannabis cultivation for medicinal and pharmaceutical purposes in Brazil
Caroline Campagnone views RDC 999/2025 favorably, allowing veterinarians authorized by CFMV to prescribe medical cannabis